Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic Cancer
ConditionPancreatic Cancer
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorChanghai Hospital
About this trial
To evaluate the safety and efficacy of neoadjuvant HRS-4642 plus chemotherapy with or without adebrelimab in patients with pancreatic ductal adenocarcinoma.
Eligibility criteria
Qualifiers
Male and female participants aged 18-70 (including those who are 18 and 70 years old)；
Pathologically or cytologically confirmed ductal adenocarcinoma of the pancreas; and subjects must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1);
Life expectancy ≥ 12 weeks;
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;
Disqualifiers
Prior receipt of any anti-tumor therapy, including but not limited to systemic chemotherapy, radiotherapy, interventional therapy, immunotherapy, targeted therapy, and anti-tumor traditional Chinese medicine therapy;
Presence of distant metastatic lesions confirmed by imaging;
Known hypersensitivity to the investigational drug or any of its excipients;
Presence of any serious or uncontrolled systemic disease;
Trial design
Treatments tested in this trial
- HRS-4642+NALIRIFOX
- HRS-4642+NALIRIFOX+Adebrelimab
- HRS-4642+NALIRIFOX+Adebrelimab
Treatment groups
60 Participants
are divided into 3 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov